Personalized Cardiovascular Medicine: Status in 2012

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 693-699

  Dandona, Sonny ^a   Roberts, Robert ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APOLIPOPROTEIN E; CLOPIDOGREL; CYTOCHROME P450 2C19; GLYCOPROTEIN IIIA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KINESIN LIKE PROTEIN 6; MENADIONE EPOXIDE; ORGANIC ANION TRANSPORTER 2; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; WARFARIN;

ASIAN; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DEATH; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG RESPONSE; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HEALTH CARE COST; HEART INFARCTION; HETEROZYGOTE; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MUSCLE CRAMP; MYALGIA; OUTCOME ASSESSMENT; PERSONALIZED CARDIOVASCULAR MEDICINE; PERSONALIZED MEDICINE; PHARMACOGENETICS; POINT OF CARE TESTING; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; THROMBOCYTE FUNCTION; WEAKNESS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; GENETIC THERAPY; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84869089697     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.08.020     Document Type: Review

References (65)

1. Roberts R. A customized genetic approach to the number one killer: coronary artery disease. Curr Opin Cardiol 2008, 23:629-633.
2. McPherson R., Pertsemlidis A., Kavaslar N., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
3. Helgadottir A., Thorleifsson G., Manolescu A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316:1491-1493.
4. Roberts R., Stewart A.F. The genetics of coronary artery disease. Curr Opin Cardiol 2012, 27:221-227.
5. Pang A.W., MacDonald J.R., Pinto D., et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol 2010, 11:R52.
6. Stranger B.E., Forrest M.S., Dunning M., et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007, 315:848-853.
7. Gibbs R.A. The International HapMap Project. Nature 2003, 426:789-796.
8. Couzin J. Drug Safety: gaps in the safety net. Science 2005, 307:196-198.
9. Altundag K., Esteva F.J., Arun B. Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anticancer Agents 2005, 5:99-106.
10. McPherson R., Davies R.W. Inflammation and coronary artery disease: insights from genetic studies. Can J Cardiol 2012, 28:662-666.
11. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799.
12. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000, 102:624-629. CLASSICS Investigators.
13. Mehta S.R., Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000, 21:2033-2041.
14. Aradi D., Komocsi A., Vorobcsuk A., et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010, 160:543-551.
15. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
16. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011, 306:1215-1223.
17. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
18. Pare G., Mehta S.R., Yusuf S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714.
19. Mega J.L., Close S.L., Wiviott S.D., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010, 376:1312-1319.
20. Wallentin L., James S., Storey R.F., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010, 376:1320-1328.
21. Bouman H.J., Schomig E., van Werkum J.W., et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011, 17:110-116.
22. Sibbing D., Koch W., Massberg S., et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011, 32:1605-1613.
23. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119:2553-2560.
24. Bell A.D., Roussin A., Cartier R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 2011, 27(suppl A):S1-S59.
25. Scott S.A., Sangkuhl K., Gardner E.E., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011, 90:328-332.
26. Roberts J.D., Wells G.A., Le May M.R., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711.
27. Hovens M.M., Snoep J.D., Eikenboom J.C., van der Bom J.G., Mertens B.J., Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007, 153:175-181.
28. Maree A.O., Curtin R.J., Chubb A., et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005, 3:2340-2345.
29. Kunicki T.J., Williams S.A., Nugent D.J., et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009, 101:123-133.
30. Li Q., Chen B.L., Ozdemir V., et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007, 8:577-586.
31. Jefferson B.K., Foster J.H., McCarthy J.J., et al. Aspirin resistance and a single gene. Am J Cardiol 2005, 95:805-808.
32. Goodman T., Ferro A., Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008, 66:222-232.
33. Piazuelo E., Fuentes J., Garcia-Gonzalez M.A., Jimenez P., Lanas A. A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin. Clin Ther 2008, 30:121-130.
34. Choi J.H., Kim S.H., Cho B.Y., et al. Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria. J Clin Pharm Ther 2009, 34:231-238.
35. Cairns J.A., Connolly S., McMurtry S., Stephenson M., Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
36. Furuya H., Fernandez-Salguero P., Gregory W., et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995, 5:389-392.
37. Rettie A.E., Haining R.L., Bajpai M., Levy R.H. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 1999, 35:253-255.
38. Carlquist J.F., Horne B.D., Muhlestein J.B., et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006, 22:191-197.
39. Takeuchi F., McGinnis R., Bourgeois S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
40. Cooper G.M., Johnson J.A., Langaee T.Y., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112:1022-1027.
41. McDonald M.G., Rieder M.J., Nakano M., Hsia C.K., Rettie A.E. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009, 75:1337-1346.
42. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
43. Lindh J.D., Holm L., Andersson M.L., Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol 2009, 65:365-375.
44. Singh O., Sandanaraj E., Subramanian K., Lee L.H., Chowbay B. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug. Metab Pharmacokinet 2011, 26:130-136.
45. Caldwell M.D., Awad T., Johnson J.A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112.
46. Limdi N.A., McGwin G., Goldstein J.A., et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008, 83:312-321.
47. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008, 358:999-1008.
48. Zhang J.E., Jorgensen A.L., Alfirevic A., et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 2009, 19:781-789.
49. Carlquist J.F., Anderson J.L. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 2011, 124:2554-2559.
50. Epstein R.S., Moyer T.P., Aubert R.E., et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010, 55:2804-2812.
51. McMillin G.A., Melis R., Wilson A., et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit 2010, 32:338-345.
52. Ross K.A., Bigham A.W., Edwards M., Gozdzik A., Suarez-Kurtz G., Parra E.J. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010, 55:582-589.
53. Anderson J.L., Horne B.D., Stevens S.M., et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012, 125:1997-2005.
54. Mangravite L.M., Thorn C.F., Krauss R.M. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006, 6:360-374.
55. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
56. Boekholdt S.M., Sacks F.M., Jukema J.W., et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005, 111:278-287.
57. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987, 113:433-440.
58. Nieminen T., Kahonen M., Viiri L.E., Gronroos P., Lehtimaki T. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 2008, 9:1475-1486.
59. Barber M.J., Mangravite L.M., Hyde C.L., et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 2010, 5:e9763.
60. Iakoubova O.A., Tong C.H., Rowland C.M., et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008, 51:435-443.
61. Iakoubova O.A., Sabatine M.S., Rowland C.M., et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2008, 51:449-455.
62. Stewart A.F., Dandona S., Chen L., et al. Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol 2009, 53:1471-1472.
63. Assimes T.L., Holm H., Kathiresan S., et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol 2010, 56:1552-1563.
64. Mancini G.B., Baker S., Bergeron J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011, 27:635-662.
65. Voora D., Shah S.H., Spasojevic I., et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.